SGLT2 Inhibition: New Insight in Cardiology
Submission Deadline: 30 Sep 2022
Guest Editors
Robert J. Chilton DO, FACC, FACP, FACOI, FAHA
Division of Cardiology, Department of Medicine, University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA
Interests: cardiovascular disease; hyperlipidemia; atherosclerosis; diabetes mellitus
Special Issue in IMR Press journals
Sinai Cardiology Faculty Group, LifeBridge Health, Baltimore, Maryland, USA
Interests: cardiovascular disease; cardio-renal medicine; hyperlipidemia
Special Issue Information
Dear Colleagues,
Diabetes is an established risk factor of cardiovascular disease and predictor of poor outcome. This explain why achieving adequate management of diabetes and hyperlipidemia, is a corner stone in most cardiology patients’ treatment plan. SGLT-2 inhibitors showed proven benefits on improving outcome in heart failure patients, both systolic and diastolic, even these who are not diabetic. As well, SGLT-2 inhibitors are recommended in diabetic patients with established cardiovascular disease for primary prevention. This emerging role of SGLT-2 inhibitors on multiple cardiac conditions, suggests this topic of SGLT-2 inhibitors: a new insight in cardiology.
Prof. Robert J. Chilton and Dr. Badr Harfouch
Guest Editors
Keywords
- heart failure
- coronary atherosclerosis
- diabetes mellitus
- SGLT-2 inhibitors
- lipo-toxicity
- metabolic inflexibility
- cardiomyocyte molecular function
Published Papers (5)
Sodium Glucose Co-Transporter Inhibition, an Expanding Impact
Rev. Cardiovasc. Med. 2023, 24(5), 130; https://doi.org/10.31083/j.rcm2405130
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Rev. Cardiovasc. Med. 2023, 24(2), 36; https://doi.org/10.31083/j.rcm2402036
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review
Rev. Cardiovasc. Med. 2023, 24(2), 32; https://doi.org/10.31083/j.rcm2402032
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Rev. Cardiovasc. Med. 2023, 24(1), 1; https://doi.org/10.31083/j.rcm2401001
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
Addressing Cardiovascular Disparities in Racial/Ethnic Populations: The Blood Pressure-Lowering Effects of SGLT2 Inhibitors
Rev. Cardiovasc. Med. 2022, 23(12), 411; https://doi.org/10.31083/j.rcm2312411
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)